{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:48Z","timestamp":1791474708945,"version":"4.3.4"},"reference-count":133,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":858,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0138","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T15:35:15Z","timestamp":1564068915000},"page":"e1236-e1250","source":"Crossref","is-referenced-by-count":54,"title":["Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs"],"prefix":"10.1093","volume":"24","author":[{"given":"Matthew J.","family":"Matasar","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and New York Presbyterian, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Unit\u00e0 Sanitaria Locale-IRCCS, Reggio Emilia, Italy"},{"name":"Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Skane University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Magagnoli","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"2021122508133668000_onco13051-bib-0001","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"suppl 5","key":"2021122508133668000_onco13051-bib-0002","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122508133668000_onco13051-bib-0003","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: Sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"2021122508133668000_onco13051-bib-0004","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/annonc\/mdv376","article-title":"Life expectancy of young adults with follicular lymphoma","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122508133668000_onco13051-bib-0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0006","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.V128.22.1777.1777","article-title":"Intervention versus observation: What is the appropriate endpoint? Assessment of endpoints in patients with advanced stage follicular lymphoma who are initially observed","volume":"128","author":"Soumerai","year":"2016","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0007","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National Lymphocare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0008","volume-title":"World Health Organization Classification of Tumours","author":"Swerdlow","year":"2008"},{"key":"2021122508133668000_onco13051-bib-0009","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.3324\/haematol.2017.175059","article-title":"Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort","volume":"103","author":"Rimsza","year":"2018","journal-title":"Haematologica"},{"key":"2021122508133668000_onco13051-bib-0010","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0011","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V101.3.1149","article-title":"Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: T(14;18) and 3q27 are mutually exclusive","volume":"101","author":"Bosga-Bouwer","year":"2003","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0012","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0013","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0014","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood-2018-03-837252","article-title":"Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles","volume":"132","author":"Hellmuth","year":"2018","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/asheducation-2005.1.314","article-title":"Biology and management of histologic transformation of indolent lymphoma","author":"Freedman","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122508133668000_onco13051-bib-0016","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0017","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0018","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: A report from the National Lymphocare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0019","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: A retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"2021122508133668000_onco13051-bib-0020","first-page":"JCO1800262","article-title":"Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: Results from two Nordic Lymphoma Group trials with more than 10 years of follow-up","author":"Lockmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0021","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"2021122508133668000_onco13051-bib-0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"2021122508133668000_onco13051-bib-0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"2021122508133668000_onco13051-bib-0024","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122508133668000_onco13051-bib-0025","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"key":"2021122508133668000_onco13051-bib-0026","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"key":"2021122508133668000_onco13051-bib-0027","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","article-title":"Activating STAT6 mutations in follicular lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0028","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: Biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J"},{"key":"2021122508133668000_onco13051-bib-0029","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"2021122508133668000_onco13051-bib-0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: A clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"2021122508133668000_onco13051-bib-0032","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia"},{"key":"2021122508133668000_onco13051-bib-0033","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122508133668000_onco13051-bib-0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24223","article-title":"Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"2021122508133668000_onco13051-bib-0035","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: Benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica"},{"key":"2021122508133668000_onco13051-bib-0036","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"2021122508133668000_onco13051-bib-0037","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0038","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0039","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National Lymphocare Study (NLCS): A prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122508133668000_onco13051-bib-0040","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0041","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0042","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0043","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: A LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0044","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12675","article-title":"Peripheral blood involvement in patients with follicular lymphoma: A rare disease manifestation associated with poor prognosis","volume":"164","author":"Sarkozy","year":"2014","journal-title":"Br J Haematol"},{"key":"2021122508133668000_onco13051-bib-0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0046","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0047","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: A retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0048","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0049","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"2021122508133668000_onco13051-bib-0050","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): Secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0051","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0052","first-page":"1490","article-title":"Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study","volume":"130","author":"Launonen","year":"2017","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0053","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"},{"key":"2021122508133668000_onco13051-bib-0054","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"2021122508133668000_onco13051-bib-0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/hon.2437_10","article-title":"Outcome of curative radiotherapy for localised follicular lymphoma in the era of 18 F-FDG PET-CT staging: An international collaborative study on behalf of ILROG","volume":"35","author":"Brady","year":"2017","journal-title":"Hematol Oncol"},{"key":"2021122508133668000_onco13051-bib-0056","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0057","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National Lymphocare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0058","first-page":"6701","article-title":"Radiotherapy for stage I\/II follicular lymphoma (FL): Is it time for a re-appraisal?","volume":"34","author":"Mondello","year":"2014","journal-title":"Anticancer Res"},{"key":"2021122508133668000_onco13051-bib-0059","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0060","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0061","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0062","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0063","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0064","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0065","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0066","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"2021122508133668000_onco13051-bib-0067","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0068","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122508133668000_onco13051-bib-0069","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"2021122508133668000_onco13051-bib-0071","first-page":"486","article-title":"Long term follow-up of the PRIMA study: Half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0072","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus chop plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2021122508133668000_onco13051-bib-0073","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0074","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0075","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: First report of the National Lymphocare Study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0076","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1002\/cncr.28350","article-title":"Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National Lymphocare Study","volume":"119","author":"Martin","year":"2013","journal-title":"Cancer"},{"key":"2021122508133668000_onco13051-bib-0077","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0078","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122508133668000_onco13051-bib-0079","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122508133668000_onco13051-bib-0080","volume-title":"Gazyva: Obinutuzumab","year":"2016"},{"key":"2021122508133668000_onco13051-bib-0081","volume-title":"Gazyvaro: obinutuzumab","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0082","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0083","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0084","volume-title":"Zydelig: idelalisib","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0085","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)30025-4","article-title":"Straying from the target","volume":"3","author":"The Lancet Haematology","year":"2016","journal-title":"Lancet Haematol"},{"key":"2021122508133668000_onco13051-bib-0086","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: The development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2021122508133668000_onco13051-bib-0087","volume-title":"Aliqopa: copanlisib","year":"2017"},{"key":"2021122508133668000_onco13051-bib-0088","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hon.2437_107","article-title":"Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma (CHRONOS-1)","volume":"35","author":"Dreyling","year":"2017","journal-title":"Hematol Oncol"},{"key":"2021122508133668000_onco13051-bib-0089","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-114842","volume-title":"Long-term efficacy and safety from the copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma","author":"Dreyling","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0090"},{"key":"2021122508133668000_onco13051-bib-0091","volume-title":"Copiktra: Duvelisib","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0092","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.V128.22.1218.1218","article-title":"Dynamo: A phase 2 study demonstrating the clinical activity of duvelisib in patients with relapsed refractory indolent non-Hodgkin lymphoma","volume":"128","author":"Flinn","year":"2016","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0093","volume-title":"AUGMENT: A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab\/placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","author":"Leonard","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0094","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","article-title":"Radioimmunotherapy of non-Hodgkin lymphomas","volume":"101","author":"Cheson","year":"2003","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0095","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0096","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"2021122508133668000_onco13051-bib-0097","volume-title":"Zevalin: Ibritumomab tiuxetan","year":"2013"},{"key":"2021122508133668000_onco13051-bib-0098","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: A National Lymphocare Study and Center for International Blood and Marrow Transplant Research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508133668000_onco13051-bib-0099","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1182\/blood.V128.22.3464.3464","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma- retrospective analysis of 2 randomized trials of the German Low Grade Lymphoma Study Group","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0100","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: A follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508133668000_onco13051-bib-0101","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hon.2553","article-title":"Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment","volume":"36","author":"Jimenez-Ubieto","year":"2018","journal-title":"Hematol Oncol"},{"key":"2021122508133668000_onco13051-bib-0102","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"2021122508133668000_onco13051-bib-0103","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0104","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2017.35.15_suppl.7502","article-title":"Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed\/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL)","volume":"35","author":"Andorsky","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116715","volume-title":"Outcomes for patients with high-risk relapsed or refractory indolent B-cell lymphoma treated with copanlisib in the CHRONOS-1 study","author":"Santoro","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0106","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: A translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2021122508133668000_onco13051-bib-0107","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0108","author":"Morschhauser","year":"2018","journal-title":"Interim update from a phase 2 multicenter study of tazemetostat, and EZH2 inhibitor, in patients with relapsed or refractory (R\/R) follicular lymphoma (FL)"},{"key":"2021122508133668000_onco13051-bib-0109","first-page":"mdy048.001-mdy048.001","article-title":"42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","volume-title":"Ann Oncol","author":"Harb","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"key":"2021122508133668000_onco13051-bib-0111","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"2021122508133668000_onco13051-bib-0112","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0113","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"2021122508133668000_onco13051-bib-0114","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3Kdelta-selective and PI3Kalpha\/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122508133668000_onco13051-bib-0115","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2018.36.15_suppl.7519","article-title":"Initial results of a dose escalation study of a selective and structurally differentiated PI3K\u03b4 inhibitor, ME-401, in relapsed\/refractory (R\/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"36","author":"Soumerai","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0116","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.beha.2017.11.003","article-title":"Novel agents for relapsed and refractory follicular lymphoma","volume":"31","author":"Cheah","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122508133668000_onco13051-bib-0118","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: Results from the open-label, multicenter, phase II dawn study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0120","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"2021122508133668000_onco13051-bib-0121","first-page":"414","article-title":"High complete response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Results of an open-label, phase II study","volume":"130","author":"Nastoupil","year":"2017","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0122","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2021122508133668000_onco13051-bib-0123","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0124","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122508133668000_onco13051-bib-0125","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood-2011-09-375139","article-title":"Lymphoma spread? Target CD47-SIRPalpha!","volume":"118","author":"Spaargaren","year":"2011","journal-title":"Blood"},{"issue":"suppl 15","key":"2021122508133668000_onco13051-bib-0126","doi-asserted-by":"crossref","first-page":"7504a","DOI":"10.1200\/JCO.2018.36.15_suppl.7504","article-title":"Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed\/refractory non-hodgkin lymphoma: Initial phase 1b\/2 results","volume":"36","author":"Advani","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508133668000_onco13051-bib-0127","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122508133668000_onco13051-bib-0128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2017.02.034","article-title":"A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas","volume":"103","author":"Zhang","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"2021122508133668000_onco13051-bib-0129","volume-title":"Polatuzumab vedotin combined with bendamustine (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refractory (R\/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL): Preliminary results of a phase Ib\/II dose-escalation study","author":"Herrera","year":"2016"},{"key":"2021122508133668000_onco13051-bib-0130","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","article-title":"Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: Preliminary safety and clinical activity of a phase Ib\/II study","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"2021122508133668000_onco13051-bib-0131","volume-title":"Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-hodgkin lymphoma (NHL): Interim safety and efficacy results from a phase 1 study","author":"Budde","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0132","volume-title":"Kymriah: tisagenlecleucel","year":"2018"},{"key":"2021122508133668000_onco13051-bib-0133","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","article-title":"Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: Interim data","volume":"128","author":"Zinzani","year":"2016","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0138","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1236\/41920111\/oncolo_24_11_e1236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1236\/41920111\/oncolo_24_11_e1236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T03:15:15Z","timestamp":1640402115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/e1236\/6439917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":133,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,7,25]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0138","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,7,25]]}}}